Client’s Testimonial:
“Thank you! I appreciate all the help and am very happy to recommend your firm…”
On March 3rd, 2016, we received another EB-1A (Alien of Extraordinary Ability) approval for a Postdoctoral Fellow in the Field of Biochemistry (Approval Notice).
General Field: Biochemistry
Position at the Time of Case Filing: Postdoctoral Fellow
Country of Origin: China
Service Center: Nebraska Service Center (BSC)
State of Residence at the Time of Filing: Indiana
Approval Notice Date: March 3rd, 2016
Processing Time: 36 Days (Premium Processing Requested)
Case Summary:
Not long ago, North America Immigration Law Group (WeGreened.com) helped a postdoctoral fellow from China attain an EB-1A (Alien of Extraordinary Ability) petition approval. Our client, who is working in the field of biochemistry, initially chose to file an EB-2 NIW (National Interest Waiver) petition as well, but canceled it when his EB-1A petition was approved just 36 days after we filed the case. The reason for such rapid adjudication was because our client opted to upgrade his EB-1A case to Premium Processing (PP) roughly a month after we filed it—the USCIS has to take action on PP petitions within 15 days whereas adjudication on regularly filed cases generally takes between 4-9 months.
Outstanding Accreditation:
Our client had the necessary credentials to file his case under EB-1A. Here are some of the key attributes that we included in our petition packet:
- Notable Publication & Citation Record
When we filed the case, our client’s work had obtained 166 citations and he had published 8 scientific articles in well-known journals.
- Impressive Peer Review Experience
The value of our client’s insights to the field was illustrated by the 16 times he assessed the work of other biochemists for four high impact scientific periodicals.
- Commendable Research Efforts
As part of our comprehensive services, we took careful measures to review and understand our client’s various research projects on utilizing techniques in biology, virology and biophysics to delineate the virus’s replication mechanisms and to develop novel antiviral drugs to treat Hepatitis B. We established that his findings undoubtedly benefit the United States pharmaceutical, medical and healthcare sectors.
Our EB1A petition packet also contained six recommendation letters contributed by other experts in the field. One of these experts wrote, “Bearing in mind the quality and consistency of [Client’s] work in biochemistry, it is practically guaranteed that his superb work will continue. With this acknowledged, it is evident that [Client] is an integral member of the biochemistry community and an asset to the United States. It would be devastating to current biochemistry research to halt [Client’s] efforts from proceeding.”
We would like to congratulate our client on his EB-1A petition approval, and we wish him the best as he continues to develop his field of biochemistry.